Gene:
HSD3B1
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  short chain dehydrogenase/reductase family 11E, member 1
Alternate Symbols:  SDR11E1
PharmGKB Accession Id: PA29486

Details

Cytogenetic Location: chr1 : p13.1 - p12
GP mRNA Boundary: chr1 : 120049826 - 120057681
GP Gene Boundary: chr1 : 120039826 - 120060681
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to HSD3B1: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomic approaches to outcome prediction in prostate cancer. Cancer. 2009. Febbo Phillip G. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008. Ross Robert W, et al. PubMed

LinkOuts

Entrez Gene:
3283
OMIM:
109715
UCSC Genome Browser:
NM_000862
RefSeq RNA:
NM_000862
RefSeq Protein:
NP_000853
RefSeq DNA:
AC_000044
AC_000133
NC_000001
NT_032977
NW_001838594
NW_922462
UniProtKB:
3BHS1_HUMAN (P14060)
Ensembl:
ENSG00000203857
GenAtlas:
HSD3B1
GeneCard:
HSD3B1
MutDB:
HSD3B1
ALFRED:
LO000269R
HuGE:
HSD3B1
Comparative Toxicogenomics Database:
3283
ModBase:
P14060
HumanCyc Gene:
HS08829
HGNC:
5217

Common Searches